Menu
Back to Journals » Cancer Management and Research » Volume 13
The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
Authors Wu X, Ye C, Wang X, Cai R, Yang J, Yu X, Zhou Y, Shen L, Zhu Y, Liu X
Received 30 September 2020
Accepted for publication 25 January 2021
Published 15 February 2021 Volume 2021:13 Pages 1517—1527
DOI https://doi.org/10.2147/CMAR.S284638
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Chien-Feng Li
Xian Wu,1,* Chaoran Ye,1,* Xingmeng Wang,2 Ruyu Cai,1 Junzhe Yang,1 Xiafei Yu,1 Yi Zhou,1 Li Shen,1 Yanhui Zhu,1 Xiaoan Liu1
1Department of Breast Surgery, The First Affiliated HospitalofNanjing Medical University, Nanjing, 210029, People’s Republic of China; 2Department of General Surgery, The First People’s Hospital of Yancheng City, Yancheng, 224006, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanhui Zhu; Xiaoan Liu Tel +86-25-68308152
Email yanhui1002@hotmail.com; liuxiaoan@126.com
Purpose: To retrospectively analyze the efficacy and toxicity of epirubicin plus cyclophosphamide followed by docetaxel (EC-D) and epirubicin plus cyclophosphamide followed by paclitaxel (EC-P) efficacy as neoadjuvant chemotherapy regiments by pathological complete response (pCR) in this study.
Methods: In total, 455 patients diagnosed with breast cancer who received NAC from January 2014 to January 2019 were enrolled. Of which, 109 patients received EC-D (E: 90, C: 600, D: 80, all in mg/m2) and 346 were treated with EC-P (E: 90, C: 600, D: 175, all in mg/m2). Efficacy of NAC regimens was evaluated by pCR, and the toxicity was studied. Chi-squared test was used at p=0.05.
Results: In EC-D, 11 patients received ypT0/isN0, and 6 of them got ypT0N0. Analogously, 67 patients receiving received EC-P obtained ypT0/isN0, and 43 people of them acquired ypT0N0. The rate of pCR in EC-P was higher than EC-D. Patients with ER (-), PR (-), Her-2 (+) and high Ki-67 index were easier to were more likely to acquire pCR. Two pCRs were described, the pCR of NAC differed according to the definition. In terms of side effects, there was no significant difference in platelet and urea, but the decrease of hemoglobin and creatinine levels after EC-P treatment was more significant than that after EC-D treatment.
Conclusion: The efficacy of EC-P is better than EC-D if pCR is to be determined as a surrogate end-point for prognosis. The patients with anemia or renal insufficiency who need to receive NAC should choose EC-D.
Keywords: neoadjuvant chemotherapy, pathological complete response, EC-D, EC-P, toxicity of anticancer drugs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.